The gospel of rheumatoid arthritis patients in China! Adamu mono-resistant biosygen SULINNO has been approved for listing in China.

Innovent Biologics announced today that SULINNO® (Recombinant human anti-TNF-alpha monoclonal antibody injection, Adamo monoantigen) has been officially approved by China's State Drug Administration (NMPA) for the treatment of rheumatoid arthritis, strong straightening spina bifida and psoriasis.
SULINNO® is Xinda Bio's third monoclonal antibody drug approved by NMPA, and previously, TYVYT® (Syndili monoantigen injection) and BYVASDA® (Beva monoantigen injection) have previously been approved by NMPA.
approval of the ® SULINNO marks the expansion of Xinta Bio into the non-tumor field.
in China, nearly 20 million people suffer from rheumatoid arthritis, severe spina bifiditis or psoriasis.
the disease not only leads to a decline in the physical fitness of patients, the quality of life and social participation of patients also decline, to the patient's family and society has a heavy financial burden.
Since adamo's listing, it has been approved worldwide for the treatment of 17 diseases, including rheumatoid arthritis, rheumatoid spina bifida, psoriasis, psoriasis arthritis, childhood idiopathic arthritis, Crohn's disease (including small crohn's disease), ulcerative colitis and urethritis, and the efficacy and safety of adamosis has been recognized worldwide.
is widely used in North America and Europe, and its remarkable efficacy has been widely recognized.
, however, the use of Adamo monoantigen in China remains limited because the price of adamu monoantigen drugs still exceeds the affordability of many ordinary patients.
Adamu monosimilar SULINNO® has similar clinical efficacy and safety to Adamo monoantigen, and its clinical results are published in The Lancet Rheumatology in 2019.
listing ® SULINNO will provide more Chinese patients with high-quality and relatively affordable adamo-resistant injections, bringing hope to more patients.
.